23 Feb 2023 14:20 CET

Issuer

Medistim ASA

(Oslo, 23rd February 2023) Medistim ASA (OSE: MEDI) is a niche market leader
within ultrasound technology with headquarters in Oslo, Norway. Medistim
develops and commercializes medical equipment for use within cardiac, vascular
and transplant surgery. Today, the company announces that they will hold a
Capital Markets Day at Grand Hotel, Oslo, on March 21st from 9 am to 11 am.
Breakfast will be served from 8:30.

Medistim is proud to announce that one of the world’s leading cardiac surgeons,
Professor John D. Puskas of Mount Sinai Health System, New York, is joining us
to talk about the past, present, and future of Coronary Artery Bypass (CABG)
surgery, the need for innovation and Medistim’s role in this. Dr. Puskas is
internationally recognized for his expertise in off-pump CABG and has performed
more than 5000 off-pump procedures since 1996. He is a global leader in the
development of minimally invasive Hybrid Coronary Revascularization, which
combines robotic bypass grafting with catheter-based stents in selected
patients. Dr. Puskas was also one of the lead investigators on the REQUEST
study, a multicenter, prospective study on the influence of Medistim’s Transit
Time Flow Measurement and High Frequency Ultrasound Imaging system in >1000
patients, published in the Journal of Thoracic and Cardiovascular Surgery 2020.

In addition, we are delighted that Chief Physician in Vascular Surgery,
Professor Pirkka Vikatmaa, Helsinki University Hospital, Finland, will enlighten
us on the need and future for open vascular surgery procedures, and the
importance of quality assessment and surgical guidance during these procedures.
Dr. Vikatmaa was previously on the board of the European Society of Vascular
Surgery (ESVS) and is currently President of the Finnish Surgical Society.
“We look forward to welcoming current and new shareholders to learn more about
the fundamentals in Medistim’s addressable markets, directly from the thought
leaders in this space,” says Medistim President and CEO, Kari E. Krogstad. “In
addition, we will provide a company update, including some direction for our
product innovation. We hope to see you there!”

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
and Norway, in addition to the about 50 distributors in Europe, Asia, Middle
East, Africa, Canada and South America. For more information, visit the
Medistim home page: www.medistim.com

Please register your participation on the following link:
https://conta.cc/3ExdsWq

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com


Source

Medistim ASA

Provider

Oslo Børs Newspoint

Company Name

MEDISTIM

ISIN

NO0010159684

Symbol

MEDI

Market

Oslo Børs